Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression

This report summarizes the available evidence on the comparative efficacy, effectiveness, and harms of 12 second-generation antidepressants: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline, trazodone, and venlafaxine in treati...

Full description

Bibliographic Details
Main Author: Gartlehner, Gerald
Corporate Authors: United States Agency for Healthcare Research and Quality, RTI International-University of North Carolina Evidence-based Practice Center
Format: eBook
Language:English
Published: Rockville, MD Agency for Healthcare Research and Quality 2007, [2007]
Series:Comparative effectiveness review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:This report summarizes the available evidence on the comparative efficacy, effectiveness, and harms of 12 second-generation antidepressants: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline, trazodone, and venlafaxine in treating patients with MDD, dysthymia, and subsyndromal depression. It also evaluates the comparative efficacy and effectiveness for maintaining remission and for treating accompanying symptoms such as anxiety, insomnia, or neurovegetative symptoms
Item Description:Title from PDF title page (viewed June 15, 2011). - "Contract No. 290-02-0016.". - "January 2007."
Physical Description:1 online resource